Fluorine-18 Bavarostat - Eikonizo Therapeutics
Alternative Names: [18F]EKZ-001; [18F]EKZ-001 PETLatest Information Update: 28 Aug 2023
At a glance
- Originator Eikonizo Therapeutics
- Class Diagnostic agents; Imaging agents; Radiopharmaceutical diagnostics
- Mechanism of Action Positron-emission tomography enhancers; Radionuclide imaging enhancers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Alzheimer's disease; Amyotrophic lateral sclerosis; Unspecified
Most Recent Events
- 28 Aug 2023 No recent reports of development identified for phase-I development in Alzheimer's-disease(Diagnosis, In volunteers) in Belgium (IV, Injection)
- 28 Aug 2023 No recent reports of development identified for phase-I development in Amyotrophic-lateral-sclerosis(Diagnosis, In volunteers) in Belgium (IV, Injection)
- 28 Aug 2023 No recent reports of development identified for phase-I development in Unspecified(Diagnosis, In volunteers) in Belgium (IV)